Mode
Text Size
Log in / Sign up
N/A N=17 Other

Comparing the Performance of a Categorical Loudness Scaling Based Fitting With a Behavioural Fitting in Adults With a Nucleus Cochlear Implant 3 Months Post-activation

Hearing Loss

Enrolled (actual)
17
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: Change in Percentage of Correct Monosyllabic Word Scores in Quiet (S0) at 50 dB SPL (Behavioural Fitting Minus Categorical Loudness Scaling Based Fitting) — 35.64; 37.15; -1.52 percentage of words correct

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Categorical loudness scaling based fitting using the research fitting system. (Device); Behavioural fitting using Custom Sound Suite (CSS 6.3) Software (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Cochlear
Primary completion
Feb 2025

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Percentage of Correct Monosyllabic Word Scores in Quiet (S0) at 50 dB SPL (Behavioural Fitting Minus Categorical Loudness Scaling Based Fitting)
35.64; 37.15; -1.52
PRIMARY
Change in Adaptive Sentence in Noise Scores Measured in Decibels (S0N0 Test Setup) (Categorical Loudness Scaling Based Fitting Minus Behavioural Fitting)
5.73; 6.02; 0.29
SECONDARY
Speech, Spatial and Qualities of Hearing Scale (SSQ12) Ratings (Behavioural Fitting Minus Categorical Loudness Scaling Based Fitting)
5.41; 5.32; 0.09
SECONDARY
Percentage Correct Monosyllabic Word Scores in Quiet (S0) at 60 dB SPL (Behavioural Fitting Minus Categorical Loudness Scaling Based Fitting)
42.78; 39.22; 3.56
SECONDARY
Adaptive Digit Triplet Test (DTT) in Noise Scores (Categorical Loudnes Scaling Based Fitting Minus Behavioural Fitting)
-3.94; -3.95; -0.0006

Summary

This study aims to collect data in newly implanted cochlear implant-recipients to inform future development of fitting methods to optimally and efficiently program a cochlear implant.

Eligibility Criteria

Inclusion Criteria

  • Aged 18 years or older (no upper age limit).
  • Post-lingually deafened defined as severe or greater sensorineural hearing loss onset after the age of 2 years as reported by the subject
  • Unilaterally implanted with the CI600 Series (CI612, CI622, CI632) or CI500 series (CI512, CI522, CI532) cochlear implant.
  • Fluent speaker in the language used to assess speech perception performance, as determined by the investigator.
  • Willingness to participate in and comply with all requirements of the protocol.
  • Willing and able to provide written informed consent

Exclusion Criteria

  • Score below 3 on the screening subset of questions from the Mobile Device Proficiency Questionnaire.
  • Subject who will be programmed with an acoustic component in the implanted ear.
  • Pure tone average (average of unaided thresholds at 0.5, 1, 2 and 4 kHz) less than or equal to 30 dB HL and aided word score of more than 80% in the contralateral ear.
  • Diagnosis of auditory neuropathy.
  • Additional health factors, known to the investigator, that would prevent or restrict participation in the evaluations, including significant visual impairment and/or dexterity issues.
  • Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator.
  • Investigator site personnel directly affiliated with this study and/or their immediate families: immediate family is defined as a spouse, parent, child, or sibling.
  • Cochlear employees or employees of Contract Research Organizations or contractors engaged by Cochlear for the purposes of this investigation.
  • Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless the other investigation was/is a Cochlear sponsored investigation and determined by the investigator or Sponsor to not impact this investigation). -
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05709223). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search